Turoctocog alfa (NovoEight®) - from design to clinical proof of concept

European Journal of Haematology

Volumn 93, Issue 5, 2014, Pages 369-376

  Ezban, Mirella ^a   Vad, Knud ^a   Kjalke, Marianne ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Haemophilia A; N8; Recombinant factor VIII; RFVIII; Turoctocog alfa

Indexed keywords

AMINO ACID; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII N8; RECOMBINANT PROTEIN; SULFATE;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SAFETY; DRUG STRUCTURE; HEMOPHILIA A; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOFILTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; THROMBOELASTOGRAPHY; VIRUS INACTIVATION; ANIMAL; BIOSYNTHESIS; CHO CELL LINE; CRICETULUS; DOG; GENE EXPRESSION; GENETICS; GLYCOSYLATION; HALF LIFE TIME; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; MOUSE; PRECLINICAL STUDY; TRANSLATIONAL PROTEIN MODIFICATION;

ANIMALS; CHO CELLS; CRICETULUS; DOGS; DRUG EVALUATION, PRECLINICAL; FACTOR VIII; GENE EXPRESSION; GLYCOSYLATION; HALF-LIFE; HEMOPHILIA A; HUMANS; KINETICS; MICE; PROTEIN MODIFICATION, TRANSLATIONAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; SULFATES; THROMBIN;

EID: 84911973391     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12366     Document Type: Review

References (44)

1. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984;312:337-42.
2. Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984;312:326-30.
3. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984;312:330-7.
4. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984;312:342-7.
5. Truett MA, Blacher R, Burke RL, Caput D, Chu C, Dina D, Hartog K, Kuo CH, Masiarz FR, Merryweather JP. Characterization of the polypeptide composition of human factor VIII: C and the nucleotide sequence and expression of the human kidney cDNA. DNA 1985;4:333-49.
6. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988;263:6352-62.
7. Burke RL, Pachl C, Quiroga M, Rosenberg S, Haigwood N, Nordfang O, Ezban M. The functional domains of coagulation factor VIII:C. J Biol Chem 1986;261:12574-8.
8. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A 1986;83:5939-42.
9. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993;81:2925-35.
10. Leyte A, Van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991;266:740-6.
11. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994;269:20095-102.
12. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009;15:1187-96.
13. Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010;16:349-59.
14. Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013;121:2108-16.
15. Christiansen ML, Balling KW, Persson E, et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010;16:878-87.
16. Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, Khan MA, Yanover C, Sauna ZE. Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci 2013;34:534-48.
17. ™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013;19:691-7.
18. ™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013;19:698-705.
19. Butler M, Meneses-Acosta A. Recent advances in technology supporting biopharmaceutical production from mammalian cells. Appl Microbiol Biotechnol 2012;96:885-94.
20. Sandberg H, Almstedt A, Brandt J, Gray E, Holmquist L, Oswaldsson U, Sebring S, Mikaelsson M. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001;85:93-100.
21. Kjalke M, Heding A, Talbo G, Persson E, Thomsen J, Ezban M. Amino acid residues 721-729 are required for full factor VIII activity. Eur J Biochem 1995;234:773-9.
22. Newell JL, Fay PJ. Acidic residues C-terminal to the A2 domain facilitate thrombin-catalyzed activation of factor VIII. Biochemistry 2008;47:8786-95.
23. Hansen JJ, Bolt G, Kjærgard K, Kristensen C, Steenstrup TD. Generation of recombinant FVIII purification antibody for manufacturing of N8. J Thromb Haemost 2013;7(Suppl 2):317-1168.
24. Jankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining 'full-length' recombinant factor VIII: a comparative structural analysis. Haemophilia 2007;13:30-7.
25. D'Amici GM, Timperio AM, Gevi F, Grazzini G, Zolla L. Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation. Electrophoresis 2010;31:2730-9.
26. Kristensen AK, Kjalke M, Klausen NK, Ezban M, Vad K. Structural comparison of a new recombinant factor VIII molecule, turoctocog alfa, and commercially available FVIII products. J Thromb Haemost 2013;11(Suppl s2):1041-2.
27. Shen BW, Spiegel PC, Chang CH, Huh JW, Lee JS, Kim J, Kim YH, Stoddard BL. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008;111:1240-7.
28. Ngo JC, Huang M, Roth DA, Furie BC, Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008;16:597-606.
29. Svensson LA, Thim L, Olsen OH, Nicolaisen EM. Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties. Biol Chem 2013;394:761-5.
30. Kaufman RJ. Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost 1998;79:1068-79.
31. Kannicht C, Ramstrom M, Kohla G, Tiemeyer M, Casademunt E, Walter O, Sandberg H. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013;131:78-88.
32. Sandberg H, Almstedt A, Brandt J, et al. Structural and functional characterization of B-domain deleted recombinant factor VIII. Semin Hematol 2001;38(2 Suppl 4):4-12.
33. Macher BA, Galili U. The Galalpha1, 3Galbeta1, 4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 2008;1780:75-88.
34. Nielsen PF, Bak S, Vandahl B. Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK-293 cells. Haemophilia 2012;18:e397-8.
35. Grancha S, Navajas R, Maranon C, Paradela A, Albar JP, Jorquera JI. Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates. Haemophilia 2011;17:709-10.
36. Elm T, Karpf DM, Ovlisen K, Pelzer H, Ezban M, Kjalke M, Tranholm M. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia 2012;18:139-45.
37. Karpf DM, Kjalke M, Thim L, Agerso H, Merricks EP, Defriess N, Nichols TC, Ezban M. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Haemophilia 2011;17:e963-8.
38. ®)-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011;17:854-9.
39. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011;17:695-702.
40. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
41. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001;114:114-20.
42. ®). Haemophilia 2012;18:782-8.
43. ™ Trials. ASH Annual Meeting Abstracts 2012;120:2228.
44. Karpf D, Kjalke M, Pelzer H, Thim L, Agerso H, Merricks E, Franck H, Raymer R, Nichols T, Ezban M. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of a new recombinant FVIII (N8) in hemophilia a dogs. J Thromb Haemost 2009;7(suppl 2):512.